Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich — Clinical Trial Site

12 Registered trials

3 Currently recruiting

Organisation

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

Location

Chorzow, Poland

Identifier

ORG-100044093

Address

Ul. Strzelcow Bytomskich 11, 41-500, Poland

Departments

-
#8004; Laboratorium Analityczne
Hematology
Oddzia Klinicznym Hematologii i Profilaktyki Chorób Nowotworowych Zespołu Szpitali Miejskich w Cho
Oddzial Hematologii I Onkologii Dzieciecej
Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych
Oddział Hematologiczny
Oddział Kliniczny Hematologii i Profilaktyki Chorób Nowotworowych

Clinical trials at this site (12)

Search interface

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending

2024-518275-64-00 Diffuse large B-cell lymphomas (DLBCL, Diffuse large B- 4
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting

2024-511267-28-00 B-cell malignancies 5 2021-02-17
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu… Recruiting

2023-503394-37-00 Acute Myeloid Leucaemia 5 2024-10-23
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Ended

2022-501522-38-00 Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; M 5 2020-09-04
Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended

2023-510537-28-00 Multiple Myeloma 5 2020-05-15
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt… Ended

2023-509976-40-00 Untreated Chronic Lymphocytic Leukemia or Small Lymphoc 5 2018-05-28
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Ended

2023-507329-40-00 1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 6 2017-09-28
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi… Ended

2023-509354-58-00 Mantle Cell Lymphoma 5 2017-07-14
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended

2023-507312-13-00 Multiple Myeloma 5 2018-11-15
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 5 2014-12-18